Oncology

Faslodex (fulvestrant) is indicated: 

• as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: 

- not previously treated with endocrine therapy, or

- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.

• in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1).

In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.

IMFINZI▼(durvalumab) is indicated as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.

Iressa is indicated as monotherapy for the treatment of adults with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating mutations of EGFR‑TK

Lynparza (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

TAGRISSO▼ (osimertinib) is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).

Zoladex® (goserelin) is a Luteinising Hormone-Releasing Hormone analogue (LHRHa). Zoladex® is available as a 3.6 mg implant and a 10.8 mg implant in a pre-filled syringe.